<DOC>
	<DOCNO>NCT01637233</DOCNO>
	<brief_summary>This substudy prospective , observational , open-label , randomise study within MARCH study . The purpose substudy investigate change cerebral function parameter 5 timepoints 96 week three different treatment arm within MARCH study . The investigator hypothesise improvement cerebral function patient randomise , part parent study , maraviroc arm . assessment CNS substudy include : 1 . Neurocognitive function assess computerised testing battery call CogState ; 2. change cerebral metabolite measure via 1H Magnetic Resonance Spectroscopy ( 1H-MRS ) In randomised maraviroc arm ( arm 2 3 ) optional Lumbar puncture week 48 . The cerebrospinal fluid use measure maraviroc level ultrasensitive CSF HIV-1 viral load . These result match level plasma .</brief_summary>
	<brief_title>MARCH Central Nervous System Substudy</brief_title>
	<detailed_description>detail , substudy MARCH</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Provision write , informed consent participation substudy Enrolled substudy either week 0 visit main study Preexisting CNS disease Recent head injury ( past three month ) Current history major depression psychosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>neurocognitive function</keyword>
	<keyword>switch study</keyword>
</DOC>